Search Within

Weinberg Fellows

Formats
  1. Meeting Abstract (1375)
  2. Journal Article (1150)
  3. Review (130)
  4. Editorial (65)
  5. Research Letter (36)
  6. Book Section (25)
  7. Correspondence (24)
  8. Guidelines (12)
  9. Conference Paper (2)
  10. Miscellaneous (1)
Groups
  1. Hematology-Oncology Fellows (2747)
  2. Department of Medicine (2704)
  3. Solid Tumor Oncology Division (2003)
  4. Hematologic Malignancies, Division of (1330)
  5. GSK Faculty (1228)
  6. Department of Pathology and Laboratory Medicine (982)

More Groups

People
  1. Michael Berger (218)
  2. Marc Ladanyi (198)
  3. Pedram Razavi (184)
  4. Michael Offin (176)
  5. Sergio Giralt (171)
  6. Maria Carlo (168)

More People

Years
  1. 2025 (207)
  2. 2024 (414)
  3. 2023 (330)
  4. 2022 (377)
  5. 2021 (339)
  6. 2020 (323)

More Years

Publications
  1. Journal of Clinical Oncology (568)
  2. Blood (299)
  3. Annals of Oncology (107)
  4. Clinical Cancer Research (102)
  5. Journal of Thoracic Oncology (96)
  6. Cancer Research (87)

More Publications

Publishers
  1. American Society of Clinical Oncology (643)
  2. Elsevier Inc. (343)
  3. American Society of Hematology (339)
  4. American Association for Cancer Research (239)
  5. Nature Publishing Group (201)
  6. Oxford University Press (157)

More Publishers

Results (2820)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Tumor testing in men with prostate cancer to predict for germline DNA-damage repair mutations
    Meeting Abstract

    Carlo, M. I.; Kemel, Y.; Breen, K.; Cadoo, K. A.; Walsh, M. F.; Abida, W.; Autio, K. A.; Danila, D. C.; Kampel, L. J.; Morris, M. J.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Characterization of actionable genetic alterations to guide targeted therapy for metastatic urothelial carcinoma
    Meeting Abstract

    Almassi, N.; Pietzak, E. J.; Funt, S. A.; Schultz, N.; Dalbagni, G.; Bochner, B. H.; Al-Ahmadie, H.; Bajorin, D. F.; Rosenberg, J. E.; Iyer, G.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Outcomes after cessation of therapy with alkylating agents (AA) for pancreatic neuroendocrine tumors (panNETs)
    Meeting Abstract

    Wu, L.; Reidy, D. L.; Bielska, A.; Kelly, V.; Raj, N. P.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Phase II study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinomas: Results of Part A (pembrolizumab alone)
    Meeting Abstract

    Mulvey, C.; Raj, N. P.; Chan, J. A.; Aggarwal, R. R.; Cinar, P.; Hope, T. A.; Kolli, K.; Zhang, L.; Calabrese, S.; Grabowsky, J. A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O-) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA)
    Meeting Abstract

    Janjigian, Y. Y.; Chou, J. F.; Simmons, M.; Momtaz, P.; Sanchez-Vega, F.; Shcherba, M.; Ku, G. Y.; Won, E.; Chong, C. R.; Gerdes, H.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Temozolomide in grade III neuroendocrine neoplasms (G3 NENs): A multicenter retrospective review
    Meeting Abstract

    Chan, D.; Bergsland, E. K.; Chan, J. A.; Gadgil, R.; Halfdanarson, T. R.; Hornbacker, K.; Kelly, V.; Kunz, P. L.; McGarrah, P. W.; Raj, N. P.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Predictors of treatment response in colorectal high-grade neuroendocrine carcinomas (HGNEC): A single institution experience
    Meeting Abstract

    Corbett, V.; Raj, N. P.; Kelly, V.; Reidy, D. L.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • ARID1A is a critical regulator of luminal identity and therapeutic response in estrogen receptor-positive breast cancer
    Meeting Abstract

    Toska, E.; Xu, G.; Chhangawala, S.; Cocco, E.; Razavi, P.; Otto, J.; Cai, Y.; Chan, C.; D'Avino, D. R.; Collings, C.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • First-in-human phase I study of the CD40 agonist mAb CDX-1140 and in combination with CDX-301 (rhFLT3L) in patients with advanced cancers: Interim results
    Meeting Abstract

    Sanborn, R. E.; Gabrail, N. Y.; Bhardwaj, N.; Gordon, M. S.; O'Hara, M.; Khalil, D.; Hawthorne, T.; Gedrich, R.; Vitale, L.; Rogalski, M.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Genomic profiling of metastatic breast cancer identifies the Hippo pathway to be a key determinant of CDK4/6 inhibitor sensitivity
    Meeting Abstract

    Razavi, P.; Li, Q.; Li, Z.; Brown, D. N.; Ping, C.; Shen, R.; Sanchez-Vega, F.; Schultz, N. D.; Baselga, J.; Scaltriti, M.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save